Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CMPX |
---|---|---|
09:32 ET | 2042 | 1.54 |
09:43 ET | 100 | 1.4726 |
09:45 ET | 350 | 1.4683 |
09:50 ET | 2100 | 1.47 |
09:52 ET | 200 | 1.475 |
09:54 ET | 590 | 1.46 |
09:57 ET | 100 | 1.4876 |
10:01 ET | 100 | 1.4876 |
10:06 ET | 950 | 1.4901 |
10:10 ET | 403 | 1.4901 |
10:12 ET | 500 | 1.485 |
10:14 ET | 1112 | 1.4995 |
10:26 ET | 100 | 1.451 |
10:30 ET | 500 | 1.47 |
10:32 ET | 200 | 1.47 |
10:33 ET | 400 | 1.47 |
10:42 ET | 500 | 1.5 |
10:44 ET | 100 | 1.48 |
11:08 ET | 200 | 1.51 |
11:11 ET | 3550 | 1.49 |
11:38 ET | 631 | 1.475 |
11:40 ET | 10218 | 1.46 |
11:42 ET | 1550 | 1.44 |
11:44 ET | 3940 | 1.46 |
11:49 ET | 993 | 1.455 |
11:54 ET | 4980 | 1.44 |
11:56 ET | 100 | 1.45 |
12:05 ET | 100 | 1.44 |
12:09 ET | 100 | 1.44 |
12:43 ET | 100 | 1.44 |
12:50 ET | 2657 | 1.45 |
01:03 ET | 100 | 1.46 |
01:12 ET | 1986 | 1.475 |
01:15 ET | 148 | 1.53 |
01:24 ET | 100 | 1.54 |
01:28 ET | 3927 | 1.4871 |
01:33 ET | 204 | 1.5198 |
01:37 ET | 400 | 1.49 |
01:39 ET | 372 | 1.47 |
01:44 ET | 500 | 1.49 |
01:51 ET | 259 | 1.4717 |
01:57 ET | 100 | 1.49 |
02:15 ET | 100 | 1.489 |
02:27 ET | 177 | 1.49 |
02:33 ET | 1600 | 1.49 |
02:40 ET | 1100 | 1.48 |
02:44 ET | 736 | 1.471 |
02:51 ET | 100 | 1.47 |
02:54 ET | 100 | 1.49 |
02:58 ET | 907 | 1.4985 |
03:05 ET | 300 | 1.485 |
03:07 ET | 3996 | 1.5 |
03:12 ET | 2400 | 1.5 |
03:14 ET | 4164 | 1.5 |
03:27 ET | 968 | 1.4991 |
03:30 ET | 4175 | 1.45 |
03:43 ET | 200 | 1.475 |
03:50 ET | 200 | 1.49 |
03:52 ET | 871 | 1.49 |
03:54 ET | 114 | 1.46 |
03:56 ET | 205 | 1.47 |
03:57 ET | 515 | 1.49 |
03:59 ET | 1441 | 1.49 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Compass Therapeutics Inc. | 205.0M | -4.5x | --- |
Trevi Therapeutics Inc | 202.7M | -10.0x | --- |
Actinium Pharmaceuticals Inc | 210.8M | -3.9x | --- |
Prelude Therapeutics Inc | 211.4M | -1.9x | --- |
Elevation Oncology Inc | 197.0M | -2.7x | --- |
Merrimack Pharmaceuticals Inc | 214.1M | -178.4x | --- |
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $205.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 137.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.33 |
Book Value | $1.16 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.